Explore
Validate
LearnAF866
antibody from R&D Systems
Targeting: CXCL14
BMAC, bolekine, BRAK, Kec, KS1, MIP-2g, NJAC, SCYB14
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF866 - Provider product page
- Provider
- R&D Systems
- Product name
- Human CXCL14/BRAK Antibody
- Antibody type
- Polyclonal
- Description
- Antigen Affinity-purified. Detects human CXCL14/BRAK in direct ELISAs and Western blots. In direct ELISAs, less than 20% cross-reactivity with recombinant mouse CXCL14/BRAK is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Unconjugated
- Antigen sequence
O95715- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Fascaplysin Exerts Anti-Cancer Effects through the Downregulation of Survivin and HIF-1α and Inhibition of VEGFR2 and TRKA.
Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively.
Oh TI, Lee YM, Nam TJ, Ko YS, Mah S, Kim J, Kim Y, Reddy RH, Kim YJ, Hong S, Lim JH
International journal of molecular sciences 2017 Sep 29;18(10)
International journal of molecular sciences 2017 Sep 29;18(10)
Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively.
Tracey L, Pérez-Rosado A, Artiga MJ, Camacho FI, Rodríguez A, Martínez N, Ruiz-Ballesteros E, Mollejo M, Martinez B, Cuadros M, Garcia JF, Lawler M, Piris MA
The Journal of pathology 2005 Jun;206(2):123-34
The Journal of pathology 2005 Jun;206(2):123-34
No comments: Submit comment
No validations: Submit validation data